Compare Stocks → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:CBMNASDAQ:EIDXNASDAQ:INSMNASDAQ:TPTXNASDAQ:ZGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMCambrex$59.99$59.99$33.80▼$60.29$2.02B2.14218,726 shsN/AEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AINSMInsmed$24.80-5.3%$27.53$17.41▼$32.00$3.68B0.921.69 million shs2.30 million shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMCambrex0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%INSMInsmed+0.11%-7.78%+0.15%-7.95%+48.50%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBMCambrexN/AN/AN/AN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AINSMInsmed3.8359 of 5 stars4.51.00.04.51.80.00.6TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMCambrexN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AINSMInsmed3.00Buy$44.6479.99% UpsideTPTXTurning Point TherapeuticsN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/ACurrent Analyst RatingsLatest INSM, ZGNX, EIDX, CBM, and TPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024INSMInsmedBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$37.00 ➝ $40.004/1/2024INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.002/27/2024INSMInsmedGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.002/27/2024INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$46.002/15/2024INSMInsmedWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMCambrex$532.09M3.80$3.91 per share15.36$19.48 per share3.08EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74INSMInsmed$305.21M12.07N/AN/A($2.32) per share-10.69TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMCambrex$92.41M$2.7721.66∞N/A5.96%5.38%2.50%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AINSMInsmed-$749.57M-$5.34N/AN/AN/A-245.59%N/A-53.34%5/2/2024 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest INSM, ZGNX, EIDX, CBM, and TPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/22/202412/31/2023INSMInsmed-$1.13-$1.28-$0.15-$1.28$82.15 million$83.70 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMCambrexN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMCambrex0.762.371.70EIDXEidos Therapeutics0.1411.1011.10INSMInsmedN/A4.123.75TPTXTurning Point TherapeuticsN/A16.8316.83ZGNXZogenix0.883.634.74OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMCambrex90.96%EIDXEidos Therapeutics31.40%INSMInsmedN/ATPTXTurning Point Therapeutics90.33%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipCBMCambrex1.41%EIDXEidos Therapeutics70.10%INSMInsmed4.60%TPTXTurning Point Therapeutics8.60%ZGNXZogenix4.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBMCambrex1,73233.72 millionN/AOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableINSMInsmed373148.55 million141.72 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableZGNXZogenix21856.23 million53.92 millionOptionableINSM, ZGNX, EIDX, CBM, and TPTX HeadlinesSourceHeadlineHwasung Industrial Co Ltd 002460morningstar.com - March 23 at 1:30 AMOrally Inhaled Dihydroergotaminemedscape.com - February 13 at 4:11 PMMRI in Headachemedscape.com - August 25 at 10:47 PMKratom: What We Knowmedscape.com - August 13 at 5:03 PMAlcon (NYSE: ALC)fool.com - July 6 at 8:34 PMLongeveron Inc Ordinary Shares - Class Amorningstar.com - May 21 at 12:24 AMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journalnews.google.com - May 10 at 11:58 PMGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern Examinernews.google.com - May 8 at 2:44 PMNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRnews.google.com - May 4 at 4:03 PMNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan Newsnews.google.com - April 28 at 12:42 PMThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headachemedscape.com - April 25 at 2:50 PMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan Newsnews.google.com - April 24 at 9:21 AMAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital Journalnews.google.com - April 24 at 9:21 AMDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital Journalnews.google.com - April 20 at 12:29 AMForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comnews.google.com - April 19 at 7:28 PMDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome Newsnews.google.com - April 18 at 3:52 PMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-Journalnews.google.com - April 17 at 7:30 PMSubcutaneous Medicine Delivery Devices Market is poised to grow ... - Digital Journalnews.google.com - April 17 at 7:30 PMEpilepsy Market to Observe Utmost CAGR of 7.78% by 2028, Size ... - Digital Journalnews.google.com - April 17 at 9:27 AMUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - PR Newswirenews.google.com - April 17 at 9:27 AMLennox Gastaut Syndrome Market to Witness Growth by 2032 | Companies-GlaxoSmithKline, Meda Pharmaceuticals, Ro - openPRnews.google.com - April 14 at 8:40 AMNeedle-Free Injectors Market Robust Expansion is expected to 2030 - Digital Journalnews.google.com - April 13 at 5:40 PMNew Trends of Long-acting Injectable Medications Market Demand: Insights and Analysis from Latest Research Rep - openPRnews.google.com - April 12 at 1:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCambrexNYSE:CBMCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Eidos TherapeuticsNASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.InsmedNASDAQ:INSMInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Turning Point TherapeuticsNASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.ZogenixNASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.